Literature DB >> 10636128

Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.

J Antinheimo1, R Sankila, O Carpén, E Pukkala, M Sainio, J Jääskeläinen.   

Abstract

OBJECTIVE: To estimate the incidence of meningiomatosis and schwannomatosis, and their familial occurrences and relation to type 2 neurofibromatosis (NF2) in a well-defined population.
METHODS: Patients with histologically verified intracranial, spinal, or peripheral schwannomas or meningiomas, who were residents of the Helsinki University Hospital catchment area (population, 1,713,000) from January 1, 1985, to December 31, 1995, were included in the study. The Population Register Center was used to identify relatives of all the patients, and their data were linked further to the Finnish Cancer Registry to find NF2-related tumors. Detailed pedigrees were constructed for the patients with NF2, schwannomatosis, meningiomatosis, patients with relatives with histologically verified schwannomas or meningiomas, and patients younger than 25 years of age at the time of diagnosis.
RESULTS: Approximately 3% (12 of 455) of the schwannoma patients had multiple schwannomas in association with NF2, and 2% (11 of 455) had schwannomatosis without NF2. Two of the patients with schwannomatosis (2 of 11) had familial schwannomatosis. Approximately 1% (7 of 823) of the patients with meningioma had multiple meningiomas in association with NF2, and 4% (29 of 823) had meningiomatosis without NF2. No families with meningiomatosis were found among the 823 patients with meningioma studied. The birth occurrence of NF2 was 1 in 87,410.
CONCLUSIONS: The current diagnostic criteria of type 2 neurofibromatosis (NF2) seem valid because NF2 patients were differentiated rather easily from patients with sporadic schwannomatosis and meningiomatosis. Familial meningiomatosis, if it truly exists, is very rare, and familial schwannomatosis is uncommon.

Entities:  

Mesh:

Year:  2000        PMID: 10636128     DOI: 10.1212/wnl.54.1.71

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  56 in total

1.  Ophthalmological manifestations in segmental neurofibromatosis type 1.

Authors:  M Ruggieri; P Pavone; A Polizzi; M Di Pietro; A Scuderi; A Gabriele; A Spalice; P Iannetti
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

Review 2.  Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Elyse R Park; Scott R Plotkin
Journal:  J Neurooncol       Date:  2015-02-07       Impact factor: 4.130

Review 3.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

4.  Incidence and mortality of neurofibromatosis: a total population study in Finland.

Authors:  Elina Uusitalo; Jussi Leppävirta; Anna Koffert; Sakari Suominen; Jussi Vahtera; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  J Invest Dermatol       Date:  2014-10-29       Impact factor: 8.551

Review 5.  [Hereditary tumor syndromes in neuropathology].

Authors:  C Mawrin
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

6.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

7.  The phosphorylation status of merlin in sporadic vestibular Schwannomas.

Authors:  Zhaoyan Wang; Yanjun Lu; Juanjuan Tang; Haojie Wang; Hao Wu
Journal:  Mol Cell Biochem       Date:  2009-01-14       Impact factor: 3.396

8.  Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.

Authors:  Yiping Shen; Fabio Nunes; Anat Stemmer-Rachamimov; Marianne James; Gayatry Mohapatra; Scott Plotkin; Rebecca A Betensky; David A Engler; Jennifer Roy; Vijaya Ramesh; James F Gusella
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

9.  Magnetic resonance findings of neurofibromatosis type 2: a case report.

Authors:  Gabriela Spilberg; Edson Marchiori; Emerson L Gasparetto; Rafael Ferracini Cabral; Tatiana Chinem Takayassu; Raquel Ribeiro Batista; Isabela Garcia Vieira
Journal:  Cases J       Date:  2009-07-02

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.